#USA #CordenPharma #North Augusta #AmbioPharm #API Peptides

CordenPharma Acquires AmbioPharm to Enhance Global Peptide Production

In a strategic move to strengthen its position in the peptide active pharmaceutical ingredient (API) sector, CordenPharma has announced the acquisition of AmbioPharm, a US-based contract development and manufacturing organization (CDMO) specializing in peptide APIs. This acquisition not only boosts CordenPharma's production capabilities in the United States, but also enhances its global expertise in handling complex peptide APIs.

With AmbioPharm's facilities located in North Augusta, South Carolina, and Shanghai, China, CordenPharma is poised to expand its production and development capabilities significantly. The integration of AmbioPharm's facilities offers CordenPharma advanced technologies for peptide synthesis, including solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid synthesis methods. This expansion enables CordenPharma to provide diverse manufacturing options and supply chain solutions to meet the growing demand for complex, high-purity peptide APIs.

Enhanced Capabilities in Peptide Manufacturing

The acquisition will increase CordenPharma's peptide manufacturing footprint within the United States. Notably, the addition of the North Augusta facility marks CordenPharma's second peptide production site in the US, amplifying their purification and freeze-drying capacities substantially. This strategic move allows CordenPharma to offer entirely US-based peptide API supply options to clients engaged in large-scale commercial peptide projects.

AmbioPharm's advanced facilities will complement CordenPharma's existing operations, allowing them to provide comprehensive support, from early-stage clinical development to commercial manufacturing. This end-to-end development process will be crucial for clients looking to navigate the complexities of peptide drug manufacturing.

Expanding the Global Reach

CordenPharma's acquisition of AmbioPharm extends its network of facilities across three continents, offering global clients an integrated approach to peptide development and production. CordenPharma will harness AmbioPharm's technological strengths to support both clinical and commercial peptide supply on a global scale, satisfying recent needs for an increased capacity in peptide synthesis methodologies.

The continued investment in expanding their peptide platform reflects CordenPharma's strategic objectives since its acquisition by Astorg in 2022, which aimed to bolster its capabilities within the peptide sector through significant infrastructural growth and technological advancements.

Positive Outlook and Future Growth

The transaction also sees AmbioPharm's shareholders reinvesting into the merged entity, signaling confidence in the enhanced capabilities and long-term growth potential of this amalgamated peptide platform. Michael Quirmbach, CEO of CordenPharma, expressed that this acquisition significantly heightens the company's ability to cater to the evolving needs of peptide production, recognizing that as peptide development becomes more sophisticated, the demand for robust CDMO partners offering reliable and diverse production pathways is critical.

Brian Gregg, CEO of AmbioPharm, shared optimism about the merger, stating the integration with CordenPharma will allow them to deliver broader technical capabilities and an expansive global reach, thus improving their ability to support peptide-based medicine development effectively.

Conclusion

Overall, this acquisition signifies an important milestone in CordenPharma's growth trajectory, enhancing its strategic position in the peptide manufacturing landscape and unlocking new opportunities for delivering peptide solutions that address the increasing demands of the pharmaceutical industry. As CordenPharma and AmbioPharm join forces, their collaborative effort is set to not only improve operational efficiencies but also ensure that patients have timely access to peptide medications that can significantly impact health outcomes. This strategic merger represents a noteworthy chapter for both entities as they leverage their strengths to meet the innovative challenges of peptide drug development in the global market.